
Muhammad Kashif Riaz , MD
Physician
Vontz Center for Molecular Studies
3125 Eden Avenue
ML 0562
Cincinnati, Ohio 45267
Phone 513-558-2119
Fax 513-558-2124
Email muhammad.riaz2@uc.edu
Education
Medical Degree: University of Health Sciences Lahore, Pakistan, 2005 (Medicine)
Internship: Shaukat Khanum Hospital Lahore, Pakistan, 2010
Residency: The Jewish Hospital Cincinnati, Ohio, 2014
Fellowship: University of Cincinnati Cincinnati, Ohio, 2017
Certifications
American Board of Internal Medicine (Hematology) (Certification Date: 10-31-2017 )
American Board of Internal Medicine (Certification Date: 08-20-2014 )
American Board of Internal Medicine (Medical Oncology) (Certification Date: 11-01-2017 )
Clinical Interests
Hematology and Oncology
Lung Cancer
Oncology
Thyroid Cancer
Bladder Cancer
Kidney Cancer
Mesothelioma
Prostate Cancer
Renal Cell Carcinoma
Testicular Cancer
Thymoma
Ureter Cancer
Urethral Cancer
Urothelial Cancer
Specialities
Hematology
Internal Medicine
Medical Oncology
Research and Practice Interests
Hematology Oncology
Positions and Work Experience
2016 -2017 Chief Fellow, University of Cincinnati,, Cincinnati, OH
2017 - Assistant Professor, University of Cincinnati,, Cincinnati, OH
2019 - Assistant Professor (Adjunct), Veterans Affair Medical Center, Cincinnati, OH
2019 - Associate Program Director, Fellowship, University of Cincinnati,, Cincinnati, OH
2018 -2020 Head & Neck Cancer Clinical Trials Leader, University of Cincinnati, Barrett Cancer Center, Cincinnati, OH
2019 - Associate Program Director, Hematology/Oncology Fellowship, University of Cincinnati,, Cincinnati, OH
2015 -2017 Hospitalist Physician, The Jewish Hospital, Cincinnati, OH
2017 - Staff Physician, University of Cincinnati,, Cincinnati, OH
2019 - Adjunct Physician, Veterans Affairs Medical Center, Cincinnati, OH
Research Support
Grant: #CA001-050 Investigators:Riaz, Muhammad 09-01-2021 -08-31-2024 Bristol-Myers Squibb Co. A Randomized, Open-label Phase 2 Clinical Trial of BMS-986012 in Combination with Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer Role:PI 532748.15 Hold Level:Industry
Grant: #PrE0506 Investigators:Riaz, Muhammad 10-01-2021 -10-01-2024 PrECOG, LLC DuRvalumab MEDI4736 with chEmotherapy as first line treAtment in advanced pleural Mesothelioma - A phase 3 Randomised trial (DREAM3R) Role:PI 74001.00 Hold Level:Industry
Investigators:Riaz, Muhammad 11-01-2021 -11-01-2024 TopAlliance Biosciences Inc. A First-in-Human, Multicenter, Open-label, Phase 1 Dose-Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAB004 as Monotherapy and in Combination Role:PI 1165367.76 Hold Level:Industry
Grant: #GMO221215; PO No.0000002543; Prime Grant No. G-18-100 Investigators:Riaz, Muhammad 01-01-2022 -02-15-2023 University of Texas Southwestern Medical Center A Phase 2 Single-Center Pharmacodynamic Study of TVB-2640 in KRAS Mutant Non-Small Cell Lung Carcinomas Role:PI 11000.00 Hold Level:Higher Education
Investigators:Riaz, Muhammad -02-15-2022 University of Texas Southwestern Medical Center A Phase 2 Single-Center Pharmacodynamic Study of TVB-2640 in KRAS Mutant Non-Small Cell Lung Carcinomas Role:PI 0.00 Hold Level:Higher Education
Publications
Peer Reviewed Publications
Gulati S.;Desai J.;Palackdharry S.M.;Morris J.C.;Zhu Z.;Jandarov R.;Riaz M.K.;Takiar V.;Mierzwa M.;Gutkind J.S.;Molinolo A.;Desai P.B.;Sadraei N.H.;Wise-Draper T.M. (01-15-2020. ) Phase 1 dose-finding study of metformin in combination with concurrent cisplatin and radiotherapy in.Cancer, , 126 (2 ) ,354-362 More Information
Haque S.;Karivedu V.;Riaz M.K.;Choi D.;Roof L.;Hassan S.Z.;Zhu Z.;Jandarov R.;Takiar V.;Tang A.;Wise-Draper T. (01-01-2019. ) High-risk pathological features at the time of salvage surgery predict poor survival after definitiv.Oral Oncology, , 88 ,9-15 More Information
Eldessouki I.;Gaber O.;Riaz M.K.;Wang J.;Karim N.A. (09-01-2018. ) Clinical presentation and treatment options for clear cell lung cancer: University of Cincinnati a c.Asian Pacific Journal of Cancer Prevention, , 19 (9 ) ,2373-2376 More Information
Riaz M.K.;Bal S.;Wise-Draper T. (09-01-2016. ) The impending financial healthcare burden and ethical dilemma of systemic therapy in metastatic canc.Journal of Surgical Oncology, , 114 (3 ) ,323-328 More Information
Professional Affiliation
2014: Diplomat American Board of Internal Medicine
2017: Diplomat American Board of Hematology
2017: Diplomat American Board of Medical Oncology
2011: American College of Physicians (ACP)
2013: American Federation for Medical Research (AFMR)
2014: American Society of Hematology (ASH)
2014: American Society of Clinical Oncology (ASCO)
2015: International Association for the Study of Lung Cancer (IASLC)
Other Information
Contact Information
Academic - Vontz Center for Molecular Studies
3125 Eden Avenue
CincinnatiĀ
Ohio, 45267
Phone: 513-558-2119
Fax: 513-558-2124
muhammad.riaz2@uc.edu